about
Secukinumab for ankylosing spondylitis and psoriatic arthritisSpondyloarthritis: Matrix Metalloproteinasesas Biomarkers of Pathogenesis and Response to Tumor Necrosis Factor (TNF) Inhibitors.Evaluation of the impact of fibromyalgia in disease activity and treatment effect in spondyloarthritisWnt/β-catenin signaling plays a key role in the development of spondyloarthritis.Chondrocyte activity is increased in psoriatic arthritis and axial spondyloarthritis.TNF-α Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab/Adalimumab in Spondyloarthritis.The role of IL-17 in the treatment of psoriatic arthritis.Human brucellosis mimicking axial spondyloarthritis: a challenge for rheumatologists when applying the 2009 ASAS criteria.Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis.Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)Predictive Factors for the Evolution of Reactive Arthritis to Ankylosing Spondylitis.Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.Genetics in TNF-TNFR pathway: A complex network causing spondyloarthritis and conditioning response to anti-TNFα therapy.Cohort identification of axial spondyloarthritis in a large healthcare dataset: current and future methodsIdentification of pathways significantly associated with spondyloarthropathy/ankylosing spondylitis using the sub‑pathway method
P2860
Q28071474-50B5D32D-32AC-4859-BA48-FA791B749072Q33624763-49EA0020-C7E9-4390-B2E6-70D4BC46E3A5Q36565726-21D32A74-7E3D-469B-9B4F-FEA417134161Q36717343-CA5551D5-8425-4952-90D0-E67C6F40268FQ37011002-218C0B25-821F-4628-A196-7542ABC0BC26Q37220061-E617C2CB-0D3A-4D4E-82C7-D8DACA448B3AQ39293096-E69E67A6-C2A0-47A2-87C9-1F8E8E8AD146Q39633472-F9E6D840-4E52-4474-BFF4-4EB2092CD417Q40916807-DD3728A8-A944-4894-8D18-4DCD3470FC96Q42137245-241222EA-1C17-4EDE-8FD2-5F45611615FFQ42293597-93D47F71-F13B-4F94-BB49-1C888A02B896Q47260079-D39C9BC3-DA64-43DB-89D2-622D21815A18Q52341767-62D7BF08-B9CF-4122-859D-ACA01AFB1E97Q57160479-8EEE3915-6F5A-4139-B278-297DD68960E5Q58767822-E0A830FB-4733-4BBE-8D1B-034C96DDB11F
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
The concept of spondyloarthritis: where are we now?
@en
type
label
The concept of spondyloarthritis: where are we now?
@en
prefLabel
The concept of spondyloarthritis: where are we now?
@en
P2093
P1476
The concept of spondyloarthritis: where are we now?
@en
P2093
Atul Deodhar
Filip van den Bosch
P304
P356
10.1016/J.BERH.2014.10.007
P577
2014-10-01T00:00:00Z